Targeting TCTP As a New Therapeutic Strategy in Castration-resistant Prostate Cancer

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2012 Aug 16

PMID 22893039

Citations 45

Authors

Virginie Baylot

Maria Katsogiannou

Claudia Andrieu

David Taieb

Julie Acunzo

Sophie Giusiano

Ladan Fazli

Martin Gleave

Carmen Garrido

Palma Rocchi

Affiliations

Soon will be listed here.

Abstract

Heat shock protein 27 (Hsp27) is highly overexpressed in castration-resistant prostate cancer (CRPC) and an antisense inhibitor (OGX-427) is currently in phase II clinical trials. In order to understand mechanisms of action of Hsp27 and find new therapeutic targets specific of CRPC, we screened for Hsp27 client proteins. Here, we report that translationally controlled tumor protein (TCTP) is a new Hsp27 client protein involved in Hsp27 cytoprotection. We found that TCTP expression is absent or weak in normal prostate cells, moderately expressed in 18.5% of treatment naive PC, and becomes uniformly and strongly expressed in 75% of CRPC. To define TCTP function, we developed and worldwide patented a TCTP antisense oligonucleotide (ASO). Interestingly, we found that CRPC progression correlates with TCTP overexpression and loss of P53. TCTP knockdown restored P53 expression and function, suggesting that castration-sensitivity is directly linked to P53 expression. Collectively, these findings provide a new Hsp27 cytoprotection mechanism in CRPC, and preclinical proof-of-concept that combining ASO-mediated TCTP knockdown with castration and/or docetaxel therapy could serve as a novel strategy to treat CRPC, with no or little toxicity for normal prostate cells.

Citing Articles

The multifaceted potential of as biomarker and therapeutic target.

Miao G, Yang Y, Yang X, Chen D, Liu L, Lei X Heliyon. 2024; 10(19):e38819.

PMID: 39397949 PMC: 11471257. DOI: 10.1016/j.heliyon.2024.e38819.

Biological role and expression of translationally controlled tumor protein (TCTP) in tumorigenesis and development and its potential for targeted tumor therapy.

Liu A, Liu J, Wang S, Ma L, Zhang J Cancer Cell Int. 2024; 24(1):198.

PMID: 38835077 PMC: 11151593. DOI: 10.1186/s12935-024-03355-9.

Advances and challenges in modeling inherited peripheral neuropathies using iPSCs.

Van Lent J, Prior R, Perez Siles G, Cutrupi A, Kennerson M, Vangansewinkel T Exp Mol Med. 2024; 56(6):1348-1364.

PMID: 38825644 PMC: 11263568. DOI: 10.1038/s12276-024-01250-x.

Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments.

Le T, Duong Q, Baylot V, Fargette C, Baboudjian M, Colleaux L Cancers (Basel). 2023; 15(20).

PMID: 37894414 PMC: 10605314. DOI: 10.3390/cancers15205047.

Harnessing the value of TCTP in breast cancer treatment resistance: an opportunity for personalized therapy.

Santamaria G, Cioce M, Rizzuto A, Fazio V, Viglietto G, Lucibello M Cancer Drug Resist. 2023; 6(3):447-467.

PMID: 37842235 PMC: 10571059. DOI: 10.20517/cdr.2023.21.

References

Baylot V, Andrieu C, Katsogiannou M, Taieb D, Garcia S, Giusiano S . OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death Dis. 2011; 2:e221. PMC: 3219088. DOI: 10.1038/cddis.2011.104. View

Calderwood S, Khaleque M, Sawyer D, Ciocca D . Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 2006; 31(3):164-72. DOI: 10.1016/j.tibs.2006.01.006. View

Burgess A, Labbe J, Vigneron S, Bonneaud N, Strub J, Van Dorsselaer A . Chfr interacts and colocalizes with TCTP to the mitotic spindle. Oncogene. 2008; 27(42):5554-66. DOI: 10.1038/onc.2008.167. View

Yarm F . Plk phosphorylation regulates the microtubule-stabilizing protein TCTP. Mol Cell Biol. 2002; 22(17):6209-21. PMC: 134017. DOI: 10.1128/MCB.22.17.6209-6221.2002. View

Joza N, Susin S, Daugas E, Stanford W, Cho S, Li C . Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature. 2001; 410(6828):549-54. DOI: 10.1038/35069004. View

Chung S, Kim M, Choi W, Chung J, Lee K . Expression of translationally controlled tumor protein mRNA in human colon cancer. Cancer Lett. 2000; 156(2):185-90. DOI: 10.1016/s0304-3835(00)00460-2. View

Kang D, Chen J, Wong J, Fang G . The checkpoint protein Chfr is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition. J Cell Biol. 2002; 156(2):249-59. PMC: 2199220. DOI: 10.1083/jcb.200108016. View

Giusiano S, Baylot V, Andrieu C, Fazli L, Gleave M, Iovanna J . TP53INP1 as new therapeutic target in castration-resistant prostate cancer. Prostate. 2012; 72(12):1286-94. DOI: 10.1002/pros.22477. View

Tannock I, de Wit R, Berry W, Horti J, Pluzanska A, Chi K . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15):1502-12. DOI: 10.1056/NEJMoa040720. View

10.

Ciocca D, Calderwood S . Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005; 10(2):86-103. PMC: 1176476. DOI: 10.1379/csc-99r.1. View

11.

Fusi A, Procopio G, Torre S, Ricotta R, Bianchini G, Salvioni R . Treatment options in hormone-refractory metastatic prostate carcinoma. Tumori. 2005; 90(6):535-46. DOI: 10.1177/030089160409000601. View

12.

Tuynder M, Susini L, Prieur S, Besse S, Fiucci G, Amson R . Biological models and genes of tumor reversion: cellular reprogramming through tpt1/TCTP and SIAH-1. Proc Natl Acad Sci U S A. 2002; 99(23):14976-81. PMC: 137530. DOI: 10.1073/pnas.222470799. View

13.

Andrieu C, Taieb D, Baylot V, Ettinger S, Soubeyran P, De-Thonel A . Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene. 2010; 29(13):1883-96. DOI: 10.1038/onc.2009.479. View

14.

Susini L, Besse S, Duflaut D, Lespagnol A, Beekman C, Fiucci G . TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ. 2008; 15(8):1211-20. DOI: 10.1038/cdd.2008.18. View

15.

Amson R, Pece S, Lespagnol A, Vyas R, Mazzarol G, Tosoni D . Reciprocal repression between P53 and TCTP. Nat Med. 2011; 18(1):91-9. DOI: 10.1038/nm.2546. View

16.

Deng S, Xing T, Zhou H, Xiong R, Lu Y, Wen B . Comparative proteome analysis of breast cancer and adjacent normal breast tissues in human. Genomics Proteomics Bioinformatics. 2006; 4(3):165-72. PMC: 5054074. DOI: 10.1016/S1672-0229(06)60029-6. View

17.

Hsu Y, Chern J, Cai Y, Liu M, Choi K . Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature. 2007; 445(7129):785-8. DOI: 10.1038/nature05528. View

18.

Thalappilly S, Suliman M, Gayet O, Soubeyran P, Hermant A, Lecine P . Identification of multi-SH3 domain-containing protein interactome in pancreatic cancer: a yeast two-hybrid approach. Proteomics. 2008; 8(15):3071-81. DOI: 10.1002/pmic.200701157. View

19.

Gibert B, Eckel B, Fasquelle L, Moulin M, Bouhallier F, Gonin V . Knock down of heat shock protein 27 (HspB1) induces degradation of several putative client proteins. PLoS One. 2012; 7(1):e29719. PMC: 3251601. DOI: 10.1371/journal.pone.0029719. View

20.

Liu H, Peng H, Cheng Y, Yuan H, Yang-Yen H . Stabilization and enhancement of the antiapoptotic activity of mcl-1 by TCTP. Mol Cell Biol. 2005; 25(8):3117-26. PMC: 1069602. DOI: 10.1128/MCB.25.8.3117-3126.2005. View